MAIN CONTENT
A survey reveals a generational divide
Released on October 25, 2026, the KB Financial Group research drew on online and mobile responses from 2,000 adults aged 25 to 69 living in major urban areas between July 21 and August 5. Overall, 10.3% reported receiving a prescription for or using a GLP-1 obesity treatment in the preceding 12 months. This is a finding about survey participants, not a verified prevalence estimate for every South Korean adult.
Gen Z, defined here as those born in or after 1995, led with 16.5%. Millennials followed at 14.2%, Generation X at 7.7% and baby boomers at 2.9%. The rate reported by men was 11.6%, against 9% for women. Looking ahead, 33.9% of respondents would consider using obesity medicines if circumstances permitted, rising to 39.7% for Gen Z. These figures do not establish which respondents had a medical indication or continued treatment.
Where clinical care meets the pressure to look a certain way
Motivation varies sharply by age. Among Gen Z respondents asked why they might consider these drugs, 48.2% selected appearance and body-shape management. Among baby boomers, 55.3% pointed to improving health.















